Stockscreener 앱 받기
1.6894
2.96%
0.0694
전일 마감가:
$1.62
열려 있는:
$1.58
하루 거래량:
620.48K
Relative Volume:
0.98
시가총액:
$61.96M
수익:
-
순이익/손실:
$-71.17M
주가수익비율:
-1.2154
EPS:
-1.39
순현금흐름:
$-70.97M
1주 성능:
+72.93%
1개월 성능:
+103.11%
6개월 성능:
-59.02%
1년 성능:
-64.81%
1일 변동 폭
$1.49
$1.695
1주일 범위
$0.9479
$1.85
52주 변동 폭
$0.721
$6.24
이노즈메 Stock (INZY) Company Profile
명칭
Inozyme Pharma Inc
전화
857-330-4340
주소
321 SUMMER STREET, BOSTON
INZY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INZY
Inozyme Pharma Inc
|
1.69 | 61.96M | 0 | -71.17M | -70.97M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.93 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.26 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
653.00 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.47 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.93 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
이노즈메 Stock (INZY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-12 | 개시 | Raymond James | Outperform |
| 2024-09-12 | 개시 | Stifel | Buy |
| 2024-08-13 | 재개 | Jefferies | Buy |
| 2024-05-30 | 개시 | Wells Fargo | Overweight |
| 2023-03-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-05-26 | 개시 | Jefferies | Hold |
| 2022-02-07 | 개시 | H.C. Wainwright | Buy |
| 2021-11-29 | 개시 | Needham | Buy |
| 2020-08-18 | 개시 | BofA Securities | Buy |
| 2020-08-18 | 개시 | Cowen | Outperform |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-18 | 개시 | Wedbush | Outperform |
모두보기
이노즈메 주식(INZY)의 최신 뉴스
Inozyme Pharma (INZY) Projected to Post Earnings on Tuesday - Defense World
JPMorgan Chase & Co. Acquires 99,944 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma Inc’s Shares Reel: -19.01% Quarterly Revenue Decline Amid 73.87M Market Cap - investchronicle.com
INZY Stock Sees Surge of Approximately 17.28% in Last Five Days - knoxdaily.com
Are Inozyme Pharma Inc’shares a good deal? - uspostnews.com
Eventide Asset Management, LLC Reduces Stake in Inozyme Pharma I - GuruFocus
Renaissance Technologies LLC Buys 256,599 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma Inc [NASDAQ: INZY] Sees Decrease in Stock Value - knoxdaily.com
Financial Snapshot: Analyzing Inozyme Pharma Inc (INZY)’s Key Ratio Metrics - DWinneX
Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Is Now A Good Time To Invest In Inozyme Pharma Inc (NASDAQ: INZY)? - Stocksregister
Wellington Management Group LLP Lowers Holdings in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Raymond James Financial Inc. Invests $205,000 in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma Inc (NASDAQ: INZY) Has Fallen -601.12% From Its Highs, What Comes Next? - Marketing Sentinel
H.C. Wainwright maintains Buy on Inozyme stock with $16 target By Investing.com - Investing.com India
H.C. Wainwright maintains Buy on Inozyme stock with $16 target - Investing.com
Inozyme Pharma (INZY) Publishes Comprehensive Study on ENPP1 Def - GuruFocus
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Rea - GuruFocus
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency - The National Law Review
INZY stock touches 52-week low at $0.77 amid market challenges - Investing.com UK
Rare Disease Innovator Inozyme Pharma Reveals Latest Progress at Elite Healthcare Conference - Stock Titan
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference - Bluefield Daily Telegraph
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Inozyme Pharma Inc (NASDAQ: INZY) Has Decreased By -82.88 Percent This Year. Is It A Better Buy Than Others? - Marketing Sentinel
Inozyme Pharma stock hits 52-week low at $0.98 amid sharp decline By Investing.com - Investing.com South Africa
Inozyme Pharma stock hits 52-week low at $0.98 amid sharp decline - Investing.com Australia
FY2027 EPS Estimates for Inozyme Pharma Raised by Analyst - Defense World
Raymond James Issues Pessimistic Forecast for Inozyme Pharma (NASDAQ:INZY) Stock Price - Defense World
Q1 Earnings Estimate for Inozyme Pharma Issued By Wedbush - Defense World
Q1 EPS Estimates for Inozyme Pharma Reduced by HC Wainwright - Defense World
Piper Sandler Has Lowered Expectations for Inozyme Pharma (NASDAQ:INZY) Stock Price - Defense World
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - insights.citeline.com
Inozyme Pharma (NASDAQ:INZY) Price Target Lowered to $15.00 at Needham & Company LLC - Defense World
Inozyme Pharma’s (INZY) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Piper Sandler cuts Inozyme Pharma stock target to $23 By Investing.com - Investing.com Australia
Inozyme Pharma stock hits 52-week low at $1.03 amid sharp decline - Investing.com
Piper Sandler cuts Inozyme Pharma stock target to $23 - Investing.com
Inozyme Pharma Focuses on ENPP1 Deficiency Program - TipRanks
Inozyme Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Wedbush Cuts Inozyme Pharma Price Target to $7 From $12, Maintains Outperform Rating - Marketscreener.com
Inozyme reports prioritization of ENPP1 Deficiency program, workforce reduction - TipRanks
Inozyme Pharma Reports 2024 Financial Results and Strategic Prioritization of ENPP1 Deficiency Program - Nasdaq
Inozyme Pharma, Inc. SEC 10-K Report - TradingView
Form 10-K Inozyme Pharma, Inc. For: Dec 31 - StreetInsider
이노즈메 (INZY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.70%
3.92%
자본화:
|
볼륨(24시간):